Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Neuroprotection in Pediatric Craniotomy
NCT02810899Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- Sep 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in brain neoplasms (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Intelligence Quotient at 3 months. Started Sep 2015; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
brain neoplasms
Beyond the preview
Go deeper on NCT02810899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810899.